were the FTSE 100 Index's top riser on Monday morning after one of its medicines was authorised for use by US regulators.The pharmaceutical giant's shares climbed 3.15 per cent, or 318p, to £104.12 as it revealed that the lung cancer drug Tagrisso, together with chemotherapy, has been approved by the US Food and Drug Administration.It follows a trial showing that those who received the combination saw their risk of death or disease progression from non-small cell lung cancer fall by 38 per cent compared to people who just took Tagrisso.
Load More
Load More